[go: up one dir, main page]

FR3107454B1 - Adjuvant de vaccin comprenant un microlatex inverse - Google Patents

Adjuvant de vaccin comprenant un microlatex inverse Download PDF

Info

Publication number
FR3107454B1
FR3107454B1 FR2001698A FR2001698A FR3107454B1 FR 3107454 B1 FR3107454 B1 FR 3107454B1 FR 2001698 A FR2001698 A FR 2001698A FR 2001698 A FR2001698 A FR 2001698A FR 3107454 B1 FR3107454 B1 FR 3107454B1
Authority
FR
France
Prior art keywords
vaccine adjuvant
reverse microlatex
microlatex
reverse
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2001698A
Other languages
English (en)
Other versions
FR3107454A1 (fr
Inventor
Dorothee Pliszczak
Arous Juliette Ben
Stéphane Monteillet
David Pujol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Original Assignee
Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2001698A priority Critical patent/FR3107454B1/fr
Application filed by Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA filed Critical Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Priority to KR1020227031834A priority patent/KR20220143706A/ko
Priority to PCT/EP2021/053873 priority patent/WO2021165312A1/fr
Priority to US17/801,224 priority patent/US20230052315A1/en
Priority to JP2022549574A priority patent/JP2023515028A/ja
Priority to CN202180016008.5A priority patent/CN115151246A/zh
Priority to MX2022010233A priority patent/MX2022010233A/es
Priority to BR112022016519A priority patent/BR112022016519A2/pt
Priority to EP21705950.0A priority patent/EP4106723A1/fr
Publication of FR3107454A1 publication Critical patent/FR3107454A1/fr
Application granted granted Critical
Publication of FR3107454B1 publication Critical patent/FR3107454B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Adjuvant de vaccin comprenant au moins un microlatex inverse, ledit microlatex inverse comprenant au moins une huile, au moins un agent tensio-actif, au moins un polymère comme par exemple un polyacrylate totalement ou partiellement neutralisé sous forme de sels de métaux alcalins ou de sel d’ammonium, ledit adjuvant de vaccin étant stérilisable dans son ensemble par filtration ou par passage à la chaleur d’un autoclave, et émulsionnable en une étape avec la phase aqueuse comprenant uniquement un antigène vaccinal.
FR2001698A 2020-02-20 2020-02-20 Adjuvant de vaccin comprenant un microlatex inverse Active FR3107454B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR2001698A FR3107454B1 (fr) 2020-02-20 2020-02-20 Adjuvant de vaccin comprenant un microlatex inverse
PCT/EP2021/053873 WO2021165312A1 (fr) 2020-02-20 2021-02-17 Adjuvant de vaccin comprenant un microlatex inverse
US17/801,224 US20230052315A1 (en) 2020-02-20 2021-02-17 Vaccine adjuvant comprising an inverse microlatex
JP2022549574A JP2023515028A (ja) 2020-02-20 2021-02-17 逆マイクロラテックスを含むワクチンアジュバント
KR1020227031834A KR20220143706A (ko) 2020-02-20 2021-02-17 인버스 마이크로라텍스를 포함하는 백신 애주번트
CN202180016008.5A CN115151246A (zh) 2020-02-20 2021-02-17 包含反相微胶乳的疫苗佐剂
MX2022010233A MX2022010233A (es) 2020-02-20 2021-02-17 Adyuvante de vacuna que comprende un microlatex inverso.
BR112022016519A BR112022016519A2 (pt) 2020-02-20 2021-02-17 Adjuvante de vacina que compreende um microlátex inverso
EP21705950.0A EP4106723A1 (fr) 2020-02-20 2021-02-17 Adjuvant de vaccin comprenant un microlatex inverse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2001698A FR3107454B1 (fr) 2020-02-20 2020-02-20 Adjuvant de vaccin comprenant un microlatex inverse
FR2001698 2020-02-20

Publications (2)

Publication Number Publication Date
FR3107454A1 FR3107454A1 (fr) 2021-08-27
FR3107454B1 true FR3107454B1 (fr) 2023-02-10

Family

ID=71452368

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2001698A Active FR3107454B1 (fr) 2020-02-20 2020-02-20 Adjuvant de vaccin comprenant un microlatex inverse

Country Status (9)

Country Link
US (1) US20230052315A1 (fr)
EP (1) EP4106723A1 (fr)
JP (1) JP2023515028A (fr)
KR (1) KR20220143706A (fr)
CN (1) CN115151246A (fr)
BR (1) BR112022016519A2 (fr)
FR (1) FR3107454B1 (fr)
MX (1) MX2022010233A (fr)
WO (1) WO2021165312A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114316132B (zh) * 2022-01-28 2023-08-01 赛纳生物科技(北京)有限公司 一种乳液聚合合成功能性聚合物微球的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US3919411A (en) 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
BR8803785A (pt) 1987-07-30 1989-02-21 Goodrich Co B F Copolimero de acido acrilico e processo para fazer um polimero de acido acrilico
US5288814A (en) 1992-08-26 1994-02-22 The B. F. Goodrich Company Easy to disperse polycarboxylic acid thickeners
FR2840909B1 (fr) 2002-06-13 2005-01-28 Seppic Sa Nouveau microlatex inverse auto reversible, son procede de preparation et ses utilisations en cosmetique et dans l'industrie
MX2008008311A (es) 2005-12-29 2009-03-04 Boehringer Ingelheim Vetmed Uso de una composicion inmunogenica de pcv2 para reducir los sintomas clinicos en cerdos.
FR2922767B1 (fr) * 2007-10-24 2009-12-18 Seppic Sa Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant.
FR2957803B1 (fr) * 2010-03-24 2012-06-01 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Diluants adjuvants de vaccins vivants pour maladies porcines
FR3026012B1 (fr) * 2014-09-23 2017-12-01 Soc D'exploitation De Produits Pour Les Industries Chimiques Seppic Administration par voie orale d'au moins une substance active pharmaceutique et/ou antigenique

Also Published As

Publication number Publication date
CN115151246A (zh) 2022-10-04
KR20220143706A (ko) 2022-10-25
MX2022010233A (es) 2023-01-18
BR112022016519A2 (pt) 2022-10-11
US20230052315A1 (en) 2023-02-16
FR3107454A1 (fr) 2021-08-27
WO2021165312A1 (fr) 2021-08-26
EP4106723A1 (fr) 2022-12-28
JP2023515028A (ja) 2023-04-12

Similar Documents

Publication Publication Date Title
FR3107454B1 (fr) Adjuvant de vaccin comprenant un microlatex inverse
CL2012000507A1 (es) Formulacion que comprende -2cloro-5-(3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)pirimidinil)-4-fluoro-n-((metil(1-metiletil)amino)sulfonil)benzamida, un tensioactivo no ionico seleccionado de copolimeros de bloque de polioxietileno-polioxi-alquileno, un tensioactivoanionico que comprende al menos un grupo arilsulfato; y agua; uso de la formulacion para controlar vegetacion no deseada; y metodo de control asociado.
WO2009144402A3 (fr) Installation pour la production de froid, de chaleur et/ou de travail
EP2711499A8 (fr) Moteur à pistons axiaux
AR090348A1 (es) Catalizador, proceso para la preparacion de dicho catalizador y uso de dicho catalizador en un proceso y en un dispositivo para la preparacion de olefinas
CU23790A3 (es) Sistema de ablación de placas guiadas por imágenes
AR030730A1 (es) Copolimeros segmentarios y dispersiones acuosas y peliculas que surgen de ellos
FR3061009B1 (fr) Composition cosmetique comprenant une ou plusieurs huile(s) polaire(s), un monoalcool aliphatique en c2-c6 et un polyol, au moins un actif hydrophile, et comprenant moins de 7% en poids d’eau
FR3061905B1 (fr) Composition comprenant du 2,3,3,3-tetrafluoropropene
AR066522A1 (es) Metodo para intercambiar calor en un sistema de transferencia de calor por compresion de vapor y un sistema de transferencia de calor por compresion de vapor que comprende un intercambiador de calor intermediario con un evaporador o condensador de doble fila
NZ700477A (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
EP2423472A3 (fr) Système et procédé de cycle de Rankine organique
BR112022015428A2 (pt) Conjunto de plataformas de filtro de tambor giratório compreendendo uma presilha
BR112015005493A2 (pt) conjunto de forquilha de direção
BR112022008826A2 (pt) Junta universal com rigidez aprimorada
EP2955286A3 (fr) Machine de construction
EA201690895A1 (ru) Офтальмологический раствор тартрата бримонидина для местного применения
FR3055149B1 (fr) Circuit ferme fonctionnant selon un cycle de rankine avec un dispositif pour l'arret d'urgence du circuit et procede utilisant un tel circuit
EP3779194A4 (fr) Ensemble corps de pompe, machine à fluide et dispositif d'échange de chaleur
AR051636A1 (es) Vacunas multivalentes para la gripe aviar
CL2020002434A1 (es) Formulación para emulsión bituminosa.
CO6511241A2 (es) Régimen de inmunizaión por sensibilización-refuerzo heteróloga
FR3069049B1 (fr) Systeme de conditionnement d'air pour vehicule automobile
CHERRY Cherry
RU179102U1 (ru) Устройство для двухсторонней передачи осевого усилия

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210827

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6